Biogen Idec Inc  

(Public, NASDAQ:BIIB)   Watch this stock  
Find more results for BIIB
294.84
-11.91 (-3.88%)
After Hours: 292.74 -2.09 (-0.71%)
Apr 24, 7:01PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 286.48 - 308.72
52 week 194.66 - 358.89
Open 307.00
Vol / Avg. 2.39M/2.07M
Mkt cap 69.94B
P/E 36.66
Div/yield     -
EPS 8.04
Shares 237.20M
Beta 1.02
Inst. own 93%
Jul 21, 2014
Q2 2014 Biogen Idec Inc. Earnings Release (Estimated) Add to calendar
Jun 9, 2014
Biogen Idec Inc. Annual Shareholder Meeting (Estimated) Add to calendar
Apr 23, 2014
Q1 2014 Biogen Idec Inc. Earnings Release
Apr 23, 2014
Q1 2014 Biogen Idec Inc. Earnings Conference Call - Webcast
Mar 3, 2014
Biogen Idec Inc. at Cowen Health Care Conference - Webcast
Feb 25, 2014
Biogen Idec Inc. at RBC Capital Markets Healthcare Conference - Webcast
Jan 29, 2014
Q4 2013 Biogen Idec Inc. Earnings Release
Jan 29, 2014
Q4 and Year End 2013 Biogen Idec Inc. Earnings Conference Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin 22.88% 27.11%
Operating margin 31.52% 36.25%
EBITD margin - 48.54%
Return on average assets 16.23% 17.09%
Return on average equity 21.68% 23.90%
Employees 6,850 -
CDP Score - 92 B

Address

225 BINNEY STREET
CAMBRIDGE, MA 2142
United States - Map
+1-781-4642000 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha
About Company - Wikipedia

Description

Biogen Idec Inc. (Biogen Idec) is a global biotechnology company. The Company discovers, develops, manufactures and markets therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. The Company�s products include AVONEX, TYSABRI, FAMPYRA, FUMADERM and RITUXAN. In September 2011, the Company acquired from the Dompe Group the noncontrolling interests in its joint venture sales affiliates in Italy and Switzerland. In April 2013, Elan Corporation, plc closed the TYSABRI (natalizumab) Collaboration Transaction with Biogen Idec.

Officers and directors

William D. Young Independent Chairman of the Board
Age: 69
Bio & Compensation  - Reuters
George A. Scangos Ph.D. Chief Executive Officer, Director
Age: 65
Bio & Compensation  - Reuters
Paul J. Clancy Chief Financial Officer, Executive Vice President - Finance
Age: 52
Bio & Compensation  - Reuters
Kenneth A. Di Pietro Executive Vice President - Human Resources
Age: 54
Bio & Compensation  - Reuters
Susan H. Alexander Esq. Executive Vice President, Chief Legal Officer and Corporate Secretary
Age: 57
Bio & Compensation  - Reuters
John G. Cox Executive Vice President - Pharmaceutical Operations and Technology
Age: 51
Bio & Compensation  - Reuters
Steven H. Holtzman Executive Vice President - Corporate Development
Age: 59
Bio & Compensation  - Reuters
Tony Kingsley Executive Vice President - Global Commercial Operations
Age: 50
Bio & Compensation  - Reuters
Douglas E. Williams Ph.D. Executive Vice President - Research and Development
Age: 55
Bio & Compensation  - Reuters
Spyros Artavanis-Tsakonas Ph.D. Senior Vice President, Chief Scientific Officer
Age: 67
Bio & Compensation  - Reuters